1-(4-chloro-3-methoxyphenyl)-2-aminoethanol | 710654-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-chloro-3-methoxyphenyl)-2-aminoethanol
• 英文别名: 2-amino-1-(4-chloro-3-methoxy-phenyl)-ethanol；2-amino-1-(4-chloro-3-methoxyphenyl)ethanol
• CAS: 710654-11-8
• 化学式: C₉H₁₂ClNO₂
• 分子量: 201.653
• InChiKey: LBNVNODDDSSXCY-UHFFFAOYSA-N

物化性质

• 沸点：
  359.0±42.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙醛 、 1-(4-chloro-3-methoxyphenyl)-2-aminoethanol 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 以44%的产率得到1-(4-chloro-3-methoxy-phenyl)-2-propylamino-ethanol
  参考文献：
  名称：

  [EN] MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION
  [FR] DERIVES DE MORPHOLINE DESTINES A ETRE UTILISES COMME AGONISTES DE LA DOPAMINE DANS LE TRAITEMENT DE LA DYSFONCTION SEXUELLE I.A.

  摘要：

  本发明提供了化合物的结构式(I)、(Ia)和(Ib)，其中：A选自C-X和N，B选自C-Y和N，R1选自H和(C1-C6)烷基，R2选自H和(C1-C6)烷基，X选自H、HO、C(O)NH2、NH2，Y选自H、HO、NH2、Br、Cl和F，Z选自H、HO、F、CONH2和CN；以及其药学上可接受的盐、溶剂合物和前药；但是：对于结构式(I)、(Ia)或(Ib)的化合物，当A为C-X时，B为C-Y时，X、Y和Z中至少一个必须是OH；对于结构式(I)的化合物，当A为C-X且B为C-Y时，Y为H，Z为H，R1为H，R2为H，则X不能是OH；这些化合物可用作多巴胺激动剂，用于治疗性功能障碍等。

  公开号：

  WO2004052372A1
• 作为产物：
  描述：

  (4-氯-3-甲氧基苯基)甲醇 在 manganese(IV) oxide 、 硼烷 、 zinc(II) iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 苯 为溶剂， 反应 27.0h， 生成 1-(4-chloro-3-methoxyphenyl)-2-aminoethanol
  参考文献：
  名称：

  Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists

  摘要：

  The isomeric 4-(3-chloro-4-hydroxyphenyl)- and 4-(4-chloro-3-hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines, the N-methyl derivative of the 4-(4-chloro-3-hydroxyphenyl) isomer, and 4-(3-hydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline were synthesized and evaluated for dopamine D-1 antagonist activity. The 4-(3-chloro-4-hydroxyphenyl) and the 4-(3-hydroxyphenyl) isomer possessed similar potencies as D-1 antagonists. Introduction of the N-methyl group enhanced potency about twofold. The "pharmacophore" for selective dopamine D-1 antagonist activity appears to be a tertiary 2-(3-hydroxyphenyl)-2-phenethylamine.

  DOI：

  10.1021/jm00393a033

文献信息

• Morpholine dopamine agonists
  申请人：Pfizer Inc.

  公开号：US20040259874A1

  公开（公告）日：2004-12-23

  The present invention provides for compounds of formula (I), (Ia) and (Ib) 1 Wherein: A is selected from C—X and N, B is selected from C—Y and N, R 1 is selected from H and (C 1 -C 6 )alkyl, R 2 is selected from H and (C 1 -C 6 )alkyl, X is selected from H, HO, C(O)NH 2 , NH 2 Y is selected from H, HO, NH 2 , Br, Cl and F Z is selected from H, HO, F, CONH 2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R 1 is H or (C 1 -C 6 )alkyl and R 2 is H or (C 1 -C 6 )alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R 1 is H and R 2 is H, then X cannot be OH; these compounds are useful as a medicament.

  本发明提供了式(I)、(Ia)和(Ib)的化合物，其中：A选择自C—X和N，B选择自C—Y和N，R1选择自H和(C1-C6)烷基，R2选择自H和(C1-C6)烷基，X选择自H、HO、C(O)NH2和NH2，Y选择自H、HO、NH2、Br、Cl和F，Z选择自H、HO、F、CONH2和CN；以及其药学上可接受的盐、溶剂和前药；但必须满足以下条件：对于式(I)、(Ia)或(Ib)的化合物，当A为C—X，B为C—Y，R1为H或(C1-C6)烷基，R2为H或(C1-C6)烷基时，X、Y和Z中至少有一个必须为OH；对于式(I)的化合物，当A为C—X，B为C—Y，Y为H，Z为H，R1为H，R2为H时，X不能为OH；这些化合物在药物方面有用。
• Morpholine Dopamine Agonists
  申请人：Allerton Moria Norfor Charlotte

  公开号：US20060235016A1

  公开（公告）日：2006-10-19

  The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R 1 is selected from H and (C 1 -C 6 )alkyl, R 2 is selected from H and (C 1 -C 6 )alkyl, X is selected from H, HO, C(O)NH 2 , NH 2 Y is selected from H, HO, NH 2 , Br, Cl and F Z is selected from H, HO F, CONH 2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R 1 is H or (C 1 -C 6 )alkyl and R 2 is H or (C 1 -C 6 )alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R 1 is H and R 2 is H, then X cannot be OH; these compounds are useful as a medicament.

  本发明提供了式(I)、(Ia)和(Ib)的化合物，其中：A选自C-X和N，B选自C-Y和N，R1选自H和（C1-C6）烷基，R2选自H和（C1-C6）烷基，X选自H、HO、C（O）NH2、NH2，Y选自H、HO、NH2、Br、Cl和F，Z选自H、HO、F、CONH2和CN；以及其药学上可接受的盐、溶剂和前药；但须注意：对于式(I)、(Ia)或(Ib)的化合物，当A为C-X，B为C-Y，R1为H或（C1-C6）烷基，R2为H或（C1-C6）烷基时，X、Y和Z中至少有一个必须为OH；对于式(I)的化合物，当A为C-X，B为C-Y，Y为H，Z为H，R1为H，R2为H时，X不能为OH。这些化合物有药用价值。
• MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN
  申请人：Ackley Michael Andrew

  公开号：US20090318451A1

  公开（公告）日：2009-12-24

  The present invention relates to use of a compound of formula (I), (Ia), or (Ib): wherein A, B, Z, R 1 and R 2 have the meanings given in the specification, as a medicament for the treatment of a number of pain conditions, particularly chronic or nociceptive pain, in a mammal.

  本发明涉及使用式（I），（Ia）或（Ib）的化合物：其中A，B，Z，R1和R2具有规范中给定的含义，作为治疗哺乳动物的许多疼痛症状，特别是慢性或伤害性疼痛的药物。
• MORPHOLINE DOPAMINE AGONISTS
  申请人：Allerton Charlotte Moria Norfor

  公开号：US20090270384A1

  公开（公告）日：2009-10-29

  The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R 1 is selected from H and (C 1 -C 6 )alkyl, R 2 is selected from H and (C 1 -C 6 )alkyl, X is selected from H, HO, C(O)NH 2 , NH 2 Y is selected from H, HO, NH 2 , Br, Cl and F Z is selected from H, HO, F, CONH 2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R 1 is H or (C 1 -C 6 )alkyl and R 2 is H or (C 1 -C 6 )alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R 1 is H and R 2 is H, then X cannot be OH; these compounds are useful as a medicament.

  本发明提供了公式(I)、(Ia)和(Ib)的化合物，其中：A从C-X和N中选择，B从C-Y和N中选择，R1从H和(C1-C6)烷基中选择，R2从H和(C1-C6)烷基中选择，X从H、HO、C(O)NH2和NH2中选择，Y从H、HO、NH2、Br、Cl和F中选择，Z从H、HO、F、CONH2和CN中选择；以及其药学上可接受的盐、溶剂和前药。但需注意以下情况：对于公式(I)、(Ia)或(Ib)的化合物，当A为C-X，B为C-Y，R1为H或(C1-C6)烷基，R2为H或(C1-C6)烷基时，X、Y和Z中至少有一个必须是OH；对于公式(I)的化合物，当A为C-X，B为C-Y，Y为H，Z为H，R1为H，R2为H时，X不能为OH。这些化合物可用作药物。
• WO2008/87512
  申请人：——

  公开号：——

  公开（公告）日：——